OSR Holdings, Inc.

# OSR Holdings, Inc. (OSRH)

This healthcare holding company develops immunotherapy candidates and regenerative medicine products across oncology and orthopedic applications. The immunotherapy portfolio includes VXM01, a glioblastoma candidate currently in phase 2 clinical trials, alongside several preclinical-stage programs targeting cancer antigens including mesothelin, WT1, CEA, and PD-L1. The company is also advancing design-augmented biologics, with DRT-102 in clinical development for spinal fusion and DRT-101 at the preclinical stage for osteoarthritis treatment.

Beyond product development, OSR Holdings operates a medical device distribution business focused on neurovascular intervention systems. The company maintains operations in the United States, Switzerland, and South Korea, with its principal office located in Bellevue, Washington. The organization is incorporated in Delaware and trades on the Nasdaq exchange.

The company operates with a lean structure of 19 full-time employees, reflecting its stage as a development-focused entity with multiple programs in varying stages of advancement from preclinical to clinical phases.